BofA analyst Craig Bijou raised the firm’s price target on Merit Medical (MMSI) to $118 from $103 and keeps a Neutral rating on the shares after the firm hosted an investor call to discuss details on the company’s commercialization strategy, reimbursement and the market opportunity for its recently PMA-approved Wrapsody. The firm thinks the Wrapsody 2025 revenue guidance of $7M-$9M is “reasonable” as it only assumes low single-digit market share, but BofA sees some risk to numbers because early adoption is likely dependent on reimbursement given the cost sensitive market, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $115 from $114 at Barrington
- Merit Medical price target raised to $116 from $114 at Piper Sandler
- Merit Medical price target raised to $128 from $127 at Canaccord
- Merit Medical Celebrates FDA Approval of WRAPSODY™
- Merit Medical price target raised to $114 from $110 at Piper Sandler
Questions or Comments about the article? Write to editor@tipranks.com